Evidence map›Paper›PMID 36580013›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.

Salah Aref, Nahed Sallam, Sherin Abd Elaziz, Osama Salama, Shaimaa Al Ashwah, Mohamed Ayed

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Salah ArefHematology Unit, Clinical Pathology Department; Mansoura University, Egypt.ORCID 0000-0002-4822-5204
Nahed SallamHematology Unit, Clinical Pathology Department; Mansoura University, Egypt.
Sherin Abd ElazizHematology Unit, Clinical Pathology Department; Mansoura University, Egypt.
Osama SalamaHematology Unit, Clinical Pathology Department; Mansoura University, Egypt.
Shaimaa Al AshwahHematology Unit, Mansoura University, Oncology Center, Mansoura University, Egypt.
Mohamed AyedHematology Unit, Clinical Pathology Department; Mansoura University, Egypt.
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRefining risk stratification of cytogenetically  normal AML (CN-AML) cases is important for decision making and tailoring of therapy. In this context genetic and epigenetic mutations was considered. Among these epigenetic regulators are DNMT3A & TET2 genes. Therefore, the aim of  this study was to determine the prevalence of DNMT3A and TET2 genes mutations and their impact on the outcome of  adult AML patients. SUBJECTS AND

methodsThe present study is cross sectional study which was conducted on 39 adult CN-AML patients at diagnosis. For all included patients sanger sequencing was done for DNMT3A exon 23 and TET2 exon 3 genes.

resultsDNMT3A mutations were detected in 8 of 39 patients (20.5%), and in 5 of 39 patients(12.8%) in TET gene. Two CN-AML  patients had combined mutations in both genes. All of the mutations detected were missense and only one was frame shift. Mutated TET2 or DNMT3A genes were significantly associated with failure of complete remission (CR) (p <0.001), higher mortality rate, shorter OS (mean=16 versus 22.7 months) and shorter DFS (mean= 9.5 versus 21.4 months) when compared to non-mutated ones.

conclusionMutated TET2 and DNMT3A detection define a subgroup of CN-AML patients with poor outcome.

Indexed as

DioxygenasesLeukemia, Myeloid, AcuteAdultCross-Sectional StudiesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Modification MethylasesHumansMutationNucleophosminPrognosisDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Modification MethylasesNucleophosminTET2 protein, humanAMLpigenetic mutationspoor outcome

Identifiers

PMID36580013
PMCPMC9971478
OpenAlexW4313328077

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.